Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback